Work with academic experts in hematology
A scholar or researcher with expertise in hematology can help business and industrial clients solve their hematology problems and conduct hematology research to get ahead on R&D. Experts on NotedSource with backgrounds in hematology include Jeffrey Townsend, Boris Leibovitch, Dushani L. Palliyaguru, Ph.D., Katelyn Katelyn Masiuk, Marina Baretti, and Mehrdad Sheikhvatan.
Jeffrey Townsend
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Interests
Other Research Interests (78)
About
Most Relevant Publications (3+)
207 total publications
Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia
Leukemia / Nov 11, 2022
Mandell, J. D., Fisk, J. N., Cyrenne, E., Xu, M. L., Cannataro, V. L., & Townsend, J. P. (2022). Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia, 36(12), 2931–2933. https://doi.org/10.1038/s41375-022-01752-5
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
Annals of Oncology / Jan 01, 2017
Choi, M., Kadara, H., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Kim, K., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Wistuba, I. I. (2017). Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 28(1), 83–89. https://doi.org/10.1093/annonc/mdw437
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
Annals of Oncology / Jan 01, 2017
Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Yoo, Y., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Herbst, R. S. (2017). Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology, 28(1), 75–82. https://doi.org/10.1093/annonc/mdw436
Boris Leibovitch
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Interests
Other Research Interests (11)
About
Most Relevant Publications (1+)
22 total publications
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
Blood / Mar 15, 2008
Marango, J., Shimoyama, M., Nishio, H., Meyer, J. A., Min, D.-J., Sirulnik, A., Martinez-Martinez, Y., Chesi, M., Bergsagel, P. L., Zhou, M.-M., Waxman, S., Leibovitch, B. A., Walsh, M. J., & Licht, J. D. (2008). The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood, 111(6), 3145–3154. https://doi.org/10.1182/blood-2007-06-092122
Dushani L. Palliyaguru, Ph.D.
Toxicologist | Aging, Nutrition and Metabolism Research Scientist | Systems Biologist
Most Relevant Research Interests
Other Research Interests (20)
About
Most Relevant Publications (1+)
21 total publications
Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane
Seminars in Oncology / Feb 01, 2016
Yang, L., Palliyaguru, D. L., & Kensler, T. W. (2016). Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane. Seminars in Oncology, 43(1), 146–153. https://doi.org/10.1053/j.seminoncol.2015.09.013
Katelyn Katelyn Masiuk
Co-Founder and CSO at Immunovec
Most Relevant Research Interests
Other Research Interests (26)
About
Most Relevant Publications (2+)
13 total publications
Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenousCYBBregulation and expression
Blood / Mar 02, 2023
Wong, R. L., Sackey, S., Brown, D., Senadheera, S., Masiuk, K., Quintos, J. P., Colindres, N., Riggan, L., Morgan, R. A., Malech, H. L., Hollis, R. P., & Kohn, D. B. (2023). Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenousCYBBregulation and expression. Blood, 141(9), 1007–1022. https://doi.org/10.1182/blood.2022016074
Enrichment of Hematopoietic Stem Cells Using Immunomagnetic Beads to Facilitate Gene Therapy
Blood / Dec 02, 2016
Masiuk, K. E., Brown, D., Urbinati, F., Hollis, R. P., & Kohn, D. B. (2016). Enrichment of Hematopoietic Stem Cells Using Immunomagnetic Beads to Facilitate Gene Therapy. Blood, 128(22), 2313–2313. https://doi.org/10.1182/blood.v128.22.2313.2313
Marina Baretti
I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.
Most Relevant Research Interests
Other Research Interests (19)
About
Most Relevant Publications (22+)
57 total publications
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
Annals of Oncology / Mar 01, 2017
Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., … Cremolini, C. (2017). Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 28(3), 555–561. https://doi.org/10.1093/annonc/mdw627
Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic
Cancer Control / Jan 01, 2021
Jia, A. Y., Popovic, A., Mohan, A. A., Zorzi, J., Griffith, P., Kim, A. K., Anders, R. A., Burkhart, R. A., Lafaro, K., Georgiades, C., Azad, N. S., Liddell, R. P., Baretti, M., Kamel, I. R., Narang, A., Yarchoan, M., & Meyer, J. (2021). Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control, 28, 107327482110099. https://doi.org/10.1177/10732748211009945
Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)
Annals of Oncology / Oct 01, 2016
Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Annals of Oncology, 27, vi233. https://doi.org/10.1093/annonc/mdw371.84
Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer
Annals of Oncology / Sep 01, 2014
Sefrioui, D., Vasseur, C., Sesboué, R., Blanchard, F., Gangloff, A., Baretti, M., Beaussire, L., Clatot, F., Dolfus, C., Sabourin, J., Michel, P., Frebourg, T., & Di Fiore, F. (2014). Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer. Annals of Oncology, 25, iv559. https://doi.org/10.1093/annonc/mdu358.48
Modified Folfoxiri in advanced Pancreatic Cancer
Annals of Oncology / Sep 01, 2012
Ginocchi, L., Vasile, E., Caponi, S., Lucchesi, M., Caparello, C., Da Prat, V., Baretti, M., Lencioni, M., Ricci, S., & Falcone, A. (2012). Modified Folfoxiri in advanced Pancreatic Cancer. Annals of Oncology, 23, ix238. https://doi.org/10.1016/s0923-7534(20)33292-0
TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)
Annals of Oncology / Sep 01, 2012
Borad, M., Reddy, S., Bahary, N., Uronis, H., Sigal, D. S., Cohn, A. L., Schelman, W., Stephenson, J., Eng, C., & Ryan, D. P. (2012). TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology, 23, ix224. https://doi.org/10.1093/annonc/mds398
1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Annals of Oncology / Sep 01, 2021
Heumann, T. R., Baretti, M., Sugar, E., Durhman, J., Liden, S., Miles, T., Lopez-Vidal, T. Y., Leatherman, J., Sharma, A., Ahuja, N., Weekes, C. D., O’Dwyer, P. J., Monga, D. K., Reiss Binder, K. A., & Azad, N. (2021). 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals of Oncology, 32, S1087–S1088. https://doi.org/10.1016/j.annonc.2021.08.797
Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram
Annals of Oncology / Sep 01, 2017
Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Morano, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., Miceli, R., & Aprile, G. (2017). Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram. Annals of Oncology, 28, v227. https://doi.org/10.1093/annonc/mdx369.052
ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND
Annals of Oncology / Oct 01, 2015
Bozzarelli, S., Rimassa, L., Giordano, L., Garassino, I., Marrari, A., Tronconi, M. C., De Sanctis, R. M., Cavina, R., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2015). ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND. Annals of Oncology, 26, vi150. https://doi.org/10.1093/annonc/mdv348.59
SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus
Annals of Oncology / Oct 01, 2019
De Jesus-Acosta, A., Crespo Herrero, G., Gómez-Dorronsoro, M. L., Alonso, V., Riesco Martinez, M. C., Custodio, A., Lopez, C., Benavent, M., Carmona Bayonas, A., Jimenez-Fonseca, P., Llanos, M., López De San Vicente, B., Arrazubi Arrula, V., Grandez, R., González-Borja, I., Goñi, S., Arozarena, I., Baretti, M., & Viudez, A. (2019). SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus. Annals of Oncology, 30, v196. https://doi.org/10.1093/annonc/mdz245.006
Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram
Annals of Oncology / Oct 01, 2017
Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008
Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram
Annals of Oncology / Oct 01, 2017
Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008
Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study
Annals of Oncology / Oct 01, 2016
Baretti, M., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Rimassa, L., & Santoro, A. (2016). Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study. Annals of Oncology, 27, vi183. https://doi.org/10.1093/annonc/mdw370.104
Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study
Annals of Oncology / Sep 01, 2016
Baretti, M., Giordano, L., Rimassa, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Personeni, N., & Santoro, A. (2016). Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study. Annals of Oncology, 27, iv48. https://doi.org/10.1093/annonc/mdw335.29
An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort
Annals of Oncology / Sep 01, 2016
Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort. Annals of Oncology, 27, iv25. https://doi.org/10.1093/annonc/mdw333.29
Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience
Annals of Oncology / Sep 01, 2016
Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, E. S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience. Annals of Oncology, 27, iv18. https://doi.org/10.1093/annonc/mdw333.03
P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer
Annals of Oncology / Jun 01, 2016
Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer. Annals of Oncology, 27, ii51. https://doi.org/10.1093/annonc/mdw199.167
O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC)
Annals of Oncology / Jun 01, 2016
Pietrantonio, F., Cremolini, C., Rimassa, L., Lonardi, S., Mennitto, A., Morano, F., Iacono, D., Berenato, R., Caporale, M., Niger, M., Marmorino, F., Bozzarelli, S., Bergamo, F., Rossini, D., Baretti, M., Battaglin, F., Bonotto, M., Loupakis, F., de Braud, F., & Miceli, R. (2016). O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC). Annals of Oncology, 27, ii122. https://doi.org/10.1093/annonc/mdw198.13
Third-Line Folfiri in Metastatic Gastric Cancer Patients
Annals of Oncology / Sep 01, 2012
Caparello, C., Vasile, E., Lencioni, M., Fabrini, M. G., Lucchesi, M., Ginocchi, L., Caponi, S., Santi, S., Ricci, S., & Falcone, A. (2012). Third-Line Folfiri in Metastatic Gastric Cancer Patients. Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33344-5
Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)
Annals of Oncology / Sep 01, 2012
Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3
Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)
Annals of Oncology / Sep 01, 2012
Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3
Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)
Annals of Oncology / Sep 01, 2012
Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3
Mehrdad Sheikhvatan
Iran University of Medical Sciences
Most Relevant Research Interests
Other Research Interests (58)
Most Relevant Publications (1+)
90 total publications
Association of R279Q and C1562T polymorphisms of matrix metalloproteinase 9 gene and increased risk for myocardial infarction in patients with premature coronary artery disease
Journal of Clinical Laboratory Analysis / Apr 28, 2017
Sheikhvatan, M., Boroumand, M. A., Behmanesh, M., & Ziaee, S. (2017). Association of R279Q and C1562T polymorphisms of matrix metalloproteinase 9 gene and increased risk for myocardial infarction in patients with premature coronary artery disease. Journal of Clinical Laboratory Analysis, 32(1), e22218. Portico. https://doi.org/10.1002/jcla.22218